Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07262138 · ClinicalTrials.gov registry record
Active Surveillance in Older Women With ER+ Breast Cancer
A clinical trial of Early Stage Estrogen Receptor (ER) Positive Breast Cancer, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07262138: Recruiting study of Early Stage Estrogen Receptor (ER) Positive Breast Cancer, sponsored by University of Pittsburgh.
NCT07262138 is a study of Early Stage Estrogen Receptor (ER) Positive Breast Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07262138, a study of Early Stage Estrogen Receptor (ER) Positive Breast Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
ACTIVE is a prospective, single-arm, phase I/IIa study examining an active surveillance strategy for small, screen-detected, luminal breast cancer. Patients aged 70 or older with clinical stage I ER+/HER2- breast cancer are eligible. The goal of this clinical trial is to learn if an active surveillance strategy (serial imaging rather than therapeutic intervention) is a safe approach to monitor small breast cancers. The main question to answer is the proportion of participants who experience tumor progression by 12 months.
Primary Outcome
Tumor progression is defined based on the following criteria: * For tumors initially staged at cT1a and cT1b, tumor progression is defined as a greater than or equal to 50% increase in the longest diameter of the target lesion, with reference to the longest diameter at the baseline time point (t = 0mo). * For tumors initially staged at cT1c, tumor progression is defined as a greater than or equal to 25% increase in the longest diameter of the target lesion, with reference to the longest diamete
Conditions Studied
Interventions
- OTHER Active Surveillance
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2030-12-31 |
What NCT07262138 shows while recruiting
NCT07262138 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Early Stage Estrogen Receptor (ER) Positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Active Surveillance is the first listed.
NCT07262138 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07262138 about?
NCT07262138 is a clinical study titled "Active Surveillance in Older Women With ER+ Breast Cancer". ACTIVE is a prospective, single-arm, phase I/IIa study examining an active surveillance strategy for small, screen-detected, luminal breast cancer. Patients aged 70 or older with clinical stage I ER+/HER2- breast cancer are eligible. The goal of this clinical trial is to learn if an active surveilla...
What is the current status of trial NCT07262138?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-11-01. Estimated completion is 2030-12-31.
What conditions does trial NCT07262138 study?
This clinical trial studies the following conditions: Early Stage Estrogen Receptor (ER) Positive Breast Cancer.
What interventions are being tested in trial NCT07262138?
The interventions under investigation include: Active Surveillance (OTHER).
Who is sponsoring clinical trial NCT07262138?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07262138 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI